Erin R. Gardner

4.3k total citations · 1 hit paper
49 papers, 2.9k citations indexed

About

Erin R. Gardner is a scholar working on Molecular Biology, Oncology and Hematology. According to data from OpenAlex, Erin R. Gardner has authored 49 papers receiving a total of 2.9k indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Molecular Biology, 23 papers in Oncology and 11 papers in Hematology. Recurrent topics in Erin R. Gardner's work include Cancer Treatment and Pharmacology (9 papers), Histone Deacetylase Inhibitors Research (8 papers) and Multiple Myeloma Research and Treatments (7 papers). Erin R. Gardner is often cited by papers focused on Cancer Treatment and Pharmacology (9 papers), Histone Deacetylase Inhibitors Research (8 papers) and Multiple Myeloma Research and Treatments (7 papers). Erin R. Gardner collaborates with scholars based in United States, Taiwan and United Kingdom. Erin R. Gardner's co-authors include William D. Figg, Susan E. Bates, Richard Piekarz, William L. Dahut, Robin Frye, William D. Figg, Alex Sparreboom, Seth M. Steinberg, Robert W. Robey and Neil Vargesson and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Oncology and Blood.

In The Last Decade

Erin R. Gardner

48 papers receiving 2.9k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Phase II Multi-Institutional Trial of the Histone Deacetylase Inhibitor Romidepsin As Monotherapy for Patients With Cutaneous T-Cell Lymphoma

2009 561 citations Richard Piekarz, Robin Frye et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Erin R. Gardner United States	25	1.5k	1.1k	324	281	256	49	2.9k
Susan L. Kelley United States	17	1.3k 0.9×	888 0.8×	310 1.0×	361 1.3×	281 1.1×	26	3.4k
Gregory D. Ayers United States	28	961 0.6×	792 0.7×	227 0.7×	291 1.0×	317 1.2×	55	2.7k
François Lokiec France	30	1.8k 1.2×	1.3k 1.2×	522 1.6×	200 0.7×	358 1.4×	143	3.3k
Jacques Jolivet Canada	29	1.7k 1.1×	1.0k 1.0×	798 2.5×	289 1.0×	411 1.6×	91	3.9k
Shuiying Hu United States	32	1.3k 0.8×	1.7k 1.6×	505 1.6×	314 1.1×	311 1.2×	94	3.5k
Cody J. Peer United States	33	1.8k 1.1×	1.5k 1.4×	172 0.5×	450 1.6×	559 2.2×	156	4.0k
Daruka Mahadevan United States	34	2.1k 1.4×	1.7k 1.5×	227 0.7×	430 1.5×	443 1.7×	144	4.0k
Benjamin Winograd Netherlands	21	928 0.6×	1.3k 1.2×	470 1.5×	223 0.8×	168 0.7×	56	2.3k
Curt Peterson Sweden	35	1.2k 0.8×	1.1k 1.0×	430 1.3×	165 0.6×	178 0.7×	128	3.5k
Wolfram E. Samlowski United States	34	1.5k 0.9×	1.6k 1.5×	239 0.7×	123 0.4×	680 2.7×	154	3.7k

Countries citing papers authored by Erin R. Gardner

Since Specialization

Citations

This map shows the geographic impact of Erin R. Gardner's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Erin R. Gardner with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Erin R. Gardner more than expected).

Fields of papers citing papers by Erin R. Gardner

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Erin R. Gardner. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Erin R. Gardner. The network helps show where Erin R. Gardner may publish in the future.

Co-authorship network of co-authors of Erin R. Gardner

This figure shows the co-authorship network connecting the top 25 collaborators of Erin R. Gardner. A scholar is included among the top collaborators of Erin R. Gardner based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Erin R. Gardner. Erin R. Gardner is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Beedie, Shaunna, Cody J. Peer, Erin R. Gardner, et al.. (2015). Anticancer Properties of a Novel Class of Tetrafluorinated Thalidomide Analogues. Molecular Cancer Therapeutics. 14(10). 2228–2237. 27 indexed citations

Peer, Cody J., Tristan M. Sissung, AeRang Kim, et al.. (2012). Sorafenib Is an Inhibitor of UGT1A1 but Is Metabolized by UGT1A9: Implications of Genetic Variants on Pharmacokinetics and Hyperbilirubinemia. Clinical Cancer Research. 18(7). 2099–2107. 108 indexed citations

Sissung, Tristan M., Erin R. Gardner, Richard Piekarz, et al.. (2010). Impact of ABCB1 Allelic Variants on QTc Interval Prolongation. Clinical Cancer Research. 17(4). 937–946. 24 indexed citations

Kelly, Ronan J., Deborah Draper, Clara C. Chen, et al.. (2010). A Pharmacodynamic Study of Docetaxel in Combination with the P-glycoprotein Antagonist Tariquidar (XR9576) in Patients with Lung, Ovarian, and Cervical Cancer. Clinical Cancer Research. 17(3). 569–580. 151 indexed citations

Gardner, Erin R., Martha J. Kelly, Eric B. Springman, et al.. (2010). Antiangiogenic and antitumor activity of LP-261, a novel oral tubulin binding agent, alone and in combination with bevacizumab. Investigational New Drugs. 30(1). 90–97. 4 indexed citations

Sun, Haihao, et al.. (2010). Bioluminescent imaging study. Cancer Biology & Therapy. 10(1). 38–43. 29 indexed citations

Grant, Clíona, Richard Piekarz, Cody J. Peer, et al.. (2010). Romidepsin: a new therapy for cutaneous T-cell lymphoma and a potential therapy for solid tumors. Expert Review of Anticancer Therapy. 10(7). 997–1008. 224 indexed citations

Erskine, Lynda, et al.. (2009). Thalidomide induces limb defects by preventing angiogenic outgrowth during early limb formation. Proceedings of the National Academy of Sciences. 106(21). 8573–8578. 181 indexed citations

Jain, Lokesh, Erin R. Gardner, William D. Figg, Milica S. Chernick, & Heidi H. Kong. (2009). Lack of Association Between Excretion of Sorafenib in Sweat and Hand‐Foot Skin Reaction. Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy. 30(1). 52–56. 28 indexed citations

10.

Sissung, Tristan M., Caitlin E. Baum, C. Tyler Kirkland, et al.. (2009). Pharmacogenetics of Membrane Transporters: An Update on Current Approaches. Molecular Biotechnology. 44(2). 152–167. 98 indexed citations

11.

Piekarz, Richard, Erin R. Gardner, Zhirong Zhan, et al.. (2008). Pharmacokinetic and biomarker analysis in a phase II trial of the HDAC inhibitor romidepsin, FK228. Cancer Research. 68. 5831–5831. 1 indexed citations

12.

Gardner, Erin R., William L. Dahut, & William D. Figg. (2008). Quantitative determination of total and unbound paclitaxel in human plasma following Abraxane treatment. Journal of Chromatography B. 862(1-2). 213–218. 42 indexed citations

13.

Chen, Xiao, Erin R. Gardner, Douglas K. Price, & William D. Figg. (2008). Development and Validation of an LC-MS Assay for Finasteride and its Application to Prostate Cancer Prevention Trial Sample Analysis. Journal of Chromatographic Science. 46(4). 356–361. 13 indexed citations

14.

Gills, Joell J., Jaclyn LoPiccolo, Junji Tsurutani, et al.. (2007). Nelfinavir, A Lead HIV Protease Inhibitor, Is a Broad-Spectrum, Anticancer Agent that Induces Endoplasmic Reticulum Stress, Autophagy, and Apoptosis In vitro and In vivo. Clinical Cancer Research. 13(17). 5183–5194. 264 indexed citations

15.

Jain, Lokesh, Erin R. Gardner, Jürgen Venitz, William L. Dahut, & William D. Figg. (2007). Development of a rapid and sensitive LC–MS/MS assay for the determination of sorafenib in human plasma. Journal of Pharmaceutical and Biomedical Analysis. 46(2). 362–367. 57 indexed citations

16.

Gardner, Erin R., Henry Burger, R VANSCHAIK, et al.. (2006). Association of enzyme and transporter genotypes with the pharmacokinetics of imatinib. Clinical Pharmacology & Therapeutics. 80(2). 192–201. 107 indexed citations

17.

Ge, Yubin, Gabriella Rustici, Wendy Freebern, et al.. (2006). Selective leukemic-cell killing by a novel functional class of thalidomide analogs. Blood. 108(13). 4126–4135. 25 indexed citations

18.

Gardner, Erin R., et al.. (2006). Determination of paclitaxel in human plasma following the administration of Genaxol or Genetaxyl by liquid chromatography/tandem mass spectrometry. Rapid Communications in Mass Spectrometry. 20(14). 2170–2174. 11 indexed citations

19.

Petersen, Sandra L., Erin R. Gardner, John P. Adelman, & Sue McCrone. (1996). Examination of steroid-induced changes in LHRH gene transcription using 33P-and 35S-labeled probes specific for intron 2.. Endocrinology. 137(1). 234–239. 38 indexed citations

20.

Gardner, Erin R., et al.. (1960). A STUDY OF THE ROLE OF ACUTE INFECTIONS IN PRECIPITATING CRISES IN CHRONIC HEMOLYTIC STATES. Annals of Internal Medicine. 52(3). 530–537. 28 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact